Atlas Arteria (ASX: ALX)- Atlas Arteria announced interim results

Atlas Arteria Group

Atlas Arteria declared net loss of $15.5 million for the six-month ended 30 June 2018, including expenses incurred on ALX’s Internalisation Proposal.

However, the group’s performance has improved during 1H18 as aggregate portfolio traffic grew 3.4% compared to the previous corresponding period delivering 6.2% increase in proportionate EBITDA from road assets to $429.1 million.

The portfolio for EBITDA contribution includes 86% from APRR, 2% from ADELAC, 11% from Greenway and 1% from Warnow. During the last six months the group has observed strong traffic growth in European assets with traffic increase of 4.6%, 2.3% and 8.4% in APRR, ADELAC and Warnow, respectively, mainly resulting from favorable economic environment and increased tourist. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Dividend of 12.0 cents per stapled security for past six months was paid on 13 April 2018. The group has confirmed distribution guidance of 12.0 cents per security for second half of 2018.

The company also indicated retirement of non-executive director of Mr. John Roberts from ATLAX Board, with effect from 28 September 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report